Skip to main content

Advertisement

SpringerLink
Log in

Diabetes

Diabetes therapy and cancer risk

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

The results of two independent, observational studies suggest that antidiabetic medications might have differential effects on cancer risk in patients with diabetes mellitus. Should these findings influence our approach to diabetes treatment?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hemkens, L. G. et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52, 1732–1744 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Libby, G. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32, 1620–1625 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Vigneri, P., Frasca, F., Sciacca, L., Pandini, G. & Vigneri, R. Diabetes and cancer. Endocr. Relat. Cancer doi:10.1677/ERC-09-0087.

    Article  CAS  PubMed  Google Scholar 

  4. Kurtzhals, P. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49, 999–1005 (2000).

    Article  CAS  PubMed  Google Scholar 

  5. Hansen, B. F. Insulin analogues with increased mitogenic potency – are they safe? Horm. Metab. Res. 40, 431–433 (2008).

    Article  CAS  PubMed  Google Scholar 

  6. Jonasson, J. M. et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52, 1745–1754 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Colhoun, H. M. et al. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52, 1755–1765 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Currie, C. J., Poole, C. D. & Gale, E. A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52, 1766–1777 (2009).

    Article  CAS  PubMed  Google Scholar 

  9. Vigneri, P., Frasca, F., Sciacca, L., Frittitta, L. & Vigneri, R. Obesity and cancer. Nutr. Metab. Cardiovasc. Dis. 16, 1–7 (2006).

    Article  CAS  PubMed  Google Scholar 

  10. Nathan, D. M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorhythm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal and Specialistic Medicine, Endocrinology, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy

    Riccardo Vigneri

Authors
  1. Riccardo Vigneri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Riccardo Vigneri.

Ethics declarations

Competing interests

The author declares an association with the following company: Sanofi-Aventis (speaker; grant/research support)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vigneri, R. Diabetes therapy and cancer risk. Nat Rev Endocrinol 5, 651–652 (2009). https://doi.org/10.1038/nrendo.2009.219

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2009.219

  • Springer Nature Limited

This article is cited by

Search

Navigation